Pemvidutide vs Zepbound: Muscle-Sparing Newcomer vs Proven Tirzepatide

Pemvidutide and Zepbound approach weight loss differently. Pemvidutide, an investigational GLP-1 and glucagon drug, stands out for preserving muscle unusually well (most of the weight lost comes from fat), and produced about 15.6% weight loss in trials, but it isn’t approved or available. Zepbound (tirzepatide) is FDA-approved, produces up to roughly 21% weight loss, and can be prescribed today, including through TrimRx. Here’s how they compare and why one is a real choice right now.

What Sets Them Apart

Pemvidutide activates the GLP-1 and glucagon receptors in a balanced 1:1 ratio. The glucagon component is thought to drive fat metabolism, especially in the liver, and pemvidutide has drawn attention for what its maker calls class-leading lean mass preservation, meaning a high share of the weight lost is fat rather than muscle. It’s a weekly injection still in development, with programs in both obesity and fatty liver disease.

Zepbound is tirzepatide, a dual GLP-1 and GIP agonist given weekly. It has large completed trials, an FDA approval for obesity (and separately for sleep apnea), and a wide real-world track record.

How They Compare on Results

The headline numbers favor Zepbound on total weight loss, but pemvidutide has its own story. In the MOMENTUM trial published in Diabetes in 2024, pemvidutide produced about 15.6% weight loss over 48 weeks, with a notably high proportion coming from fat rather than lean tissue. Zepbound, in its SURMOUNT trials, produced up to about 21%. So Zepbound wins on the scale, while pemvidutide’s distinguishing feature is body composition and its lipid and liver benefits.

Why One Is a Real Choice Today

Pemvidutide’s muscle-preservation profile is genuinely interesting, especially for anyone worried about losing lean tissue during weight loss. But it remains investigational, with its lead phase 3 program focused on fatty liver disease and its obesity development still progressing. It can’t be prescribed.

Zepbound is available now, with more total weight loss and a long safety record. TrimRx prescribes tirzepatide in both compounded and brand-name forms after a provider review, and muscle can be protected on any weight-loss drug through resistance training and adequate protein. You can see how to get started on the TrimRx homepage or by taking the quiz.

Consider a hypothetical patient focused on keeping muscle as he loses weight. Pemvidutide’s design appeals to him, but since it isn’t available, a practical alternative is tirzepatide paired with strength training and enough protein, which protects muscle while delivering larger weight loss now.

Frequently Asked Questions

Is pemvidutide available yet?

No. Pemvidutide is investigational, with its lead phase 3 program in fatty liver disease and its obesity program still in development. It cannot be prescribed today.

Is pemvidutide better than Zepbound?

Zepbound produces more total weight loss (up to about 21% versus 15.6%), while pemvidutide’s edge is preserving muscle and improving lipids and liver fat. Zepbound is also available now, whereas pemvidutide is not.

Can I get Zepbound through TrimRx?

Yes. TrimRx prescribes tirzepatide (the drug in Zepbound) in both compounded and brand-name forms, after a licensed provider reviews your health profile.

To see whether tirzepatide fits your situation, you can take the TrimRx quiz for a licensed provider’s review.

This article is for educational purposes and is not medical advice. Pemvidutide is investigational and not FDA-approved or available. Trial figures are preliminary and may change. Consult a qualified healthcare provider. Individual results vary.